Inovações de gestão no sector da saúde

Mestrado em Intervenção Sócio-Organizacional na Saúde - Área de especialização: Políticas de Administração e Gestão dos Serviços de Saúde

ERICA: smoking prevalence in Brazilian adolescents

ABSTRACT OBJECTIVE To estimate the prevalences of tobacco use, tobacco experimentation, and frequent smoking among Brazilian adolescents. METHODS We evaluated participants of the cross-sectional, nation-wide, school-based Study of Cardiovascular Risks in Adolescents (ERICA), which included 12- to 17-year-old adolescents from municipalities of over 100 thousand inhabitants. The study sample had a clustered, stratified design and was representative of the whole country, its geographical regions, and all 27 state capitals. The information was obtained with self-administered questionnaires. Tobacco experimentation was defined as having tried cigarettes at least once in life. Adolescents who had smoked on at least one day over the previous 30 days were considered current cigarette smokers. Having smoked cigarettes for at least seven consecutive days was an indicator for regular consumption of tobacco. Considering the complex sampling design, prevalences and 95% confidence intervals were estimated according to sociodemographic and socio-environmental characteristics. RESULTS We evaluated 74,589 adolescents. Among these, 18.5% (95%CI 17.7-19.4) had smoked at least once in life, 5.7% (95%CI 5.3-6.2) smoked at the time of the research, and 2.5% (95%CI 2.2-2.8) smoked often. Adolescents aged 15 to 17 years had higher prevalences for all indicators than those aged 12 to 14 years. The prevalences did not differ significantly between sexes. The highest prevalences were found in the South region and the lowest ones, in the Northeast region. Regardless of sex, the prevalences were found to be higher for adolescents who had had paid jobs, who lived with only one parent, and who reported having been in contact with smokers either inside or outside their homes. Female public school adolescents were found to smoke more than the ones from private schools. CONCLUSIONS Tobacco use among adolescents is still a challenge. Intending to reduce the prevalence of tobacco use among young people, especially the ones under socioeconomic vulnerability conditions, Brazil must consolidate and increase effective public health care measures.

Transcranial magnetic resonance guided focused ultrasound: neurosurgery applications

Mestrado em Radiações Aplicadas às Tecnologias da Saúde

A felicidade não tem idade: projeto de teatro e comunidade com seniores: trabalho de projeto

Trabalho de Projeto submetido à Escola Superior de Teatro e Cinema para cumprimento dos requisitos necessários à obtenção do grau de Mestre em Teatro – especialização em Teatro e Comunidade.

Comportamentos de sexo seguro em individuos infectados por VIH

A investigação científica que se seguiu à descoberta da infecção pelo vírus da imunodeficiência humana (VIH) representou um marco histórico importante, permitindo a instituição de terapêutica e alterando a história natural da infecção, melhorando as expectativas dos indivíduos infectados.Se, por um lado, a terapêutica antirretroviral de alta eficácia (do inglês, Highly Active Antiretroviral Theraphy: HAART), nos países desenvolvidos, teve um enorme impacto na melhoria da qualidade de vida e esperança média de vida dos indivíduos infectados, permitindo-lhes encarar a infecção como uma doença crónica, por outro lado, introduziu-se uma nova dinâmica epidemiológica na transmissão de VIH e um novo desafio para a sua prevenção.Os comportamentos sexuais são o factor-alvo através do qual se pode, de uma forma mais eficaz, prevenir a possibilidade de infectar um qualquer indivíduo na comunidade. Parece, pois, importante haver necessidade de um olhar atento da Saúde Pública sobre a vida sexual dos indivíduos infectados, não só na tentativa de, promover a sua qualidade de vida, como também, de prevenir a disseminação da doença, e, ainda mais importante, prevenir a disseminação do vírus nas suas formas resistentes.O objectivo deste estudo foi analisar a consistência do uso de preservativo/práticas de sexo seguro, em indivíduos infectados por VIH, seguidos em Consulta de Imunodepressão, do Serviço de Doenças Infecciosas, do Hospital de Santa Maria. Pretende-se avaliar, no âmbito da “Educação para a Saúde”, a necessidade de aconselhamento aos indivíduos infectados, relativamente aos seus comportamentos sexuais.Para o efeito, realizou-se um estudo descritivo e transversal. A população envolvida compreendeu todos os indivíduos infectados seguidos na Consulta de Imunodepressão. A amostra foi seleccionada através de aleatorização simples e constituída por 98 elementos. A colheita de dados foi efectuada através do método de entrevista, a qual só teve início após a assinatura do consentimento informado. O estudo decorreu entre 14 de Março e 27 de Junho de 2008.Foram analisados os dados relativamente às variáveis: sócio-demográficas, estado serológico da infecção, história sexual, consumo de substâncias, comportamento sexual e percepção de risco da transmissão da infecção por VIH.Os comportamentos de sexo não seguro foram associados ao número de parceiros sexuais/ano (p=0,007), ter parceiro sexual habitual (p=0,010), ter múltiplos parceiros sexuais ocasionais (p=0,000) e à prática de sexo oral (sexo oral receptivo, p=0,001; sexo oral activo, p=0,006).Os resultados demonstraram a importância da prevenção secundária nos indivíduos infectados por VIH. A necessidade dos centros de atendimento estarem providos de mensagem de prevenção, ensinos e aconselhamento a todas as pessoas infectadas e, também, aos seus parceiros sexuais, aumentando-lhes a qualidade de vida e reduzindo o risco de transmissão da infecção por HIV. ABSTRACT: The scientific research that followed the finding of human immunodeficiency virus (HIV) infection represented an important historical mark, allowing therapeutic institution and changing the natural history of the infection, thus improving the expectations of infected individuals. If by one side the Highly Active Antiretroviral Therapy (HAART) had an enormous impact on the improvement of life quality and life expectancy of the infected individuals on the developed countries, allowing them to face the infection as a chronic disease, on the other side it was introduced a epidemiologic dynamic on the HIV transmission and a new challenge for its prevention. Sexual behaviour is the main factor through which is possible to prevent more efficiently the possibility of infection of a community’s individual. Thus it appears important the need of Public Health to have a careful look into the sexual life of infected individuals, not only to try to promote their life quality but as well to prevent the dissemination of the disease and more importantly prevent the dissemination of the virus in its resistant forms. The objective of this study was to analyse the consistency of the use of condoms/safe sex by individuals infected by HIV that are followed by the Infectious Disease Service of the Santa Maria Hospital through Immune-depression Appointments. The goal was to evaluate the need of advisement to the infected individuals relatively to their sexual behaviours. For that it was done a descriptive and transversal study. The involved population included all infected individuals followed in the Immune-depression Appointments. The sample was selected by simple randomisation and was composed by 98 elements. The data was obtained by interview method, which was initiated after signing the informed consent. The study was took place between 14 March and 27 June 2008. It was analysed the data relative to the variables: socio-demographics, serologic state of the infection, sexual history, substances consumption, sexual behaviour and risk perception on the transmission of HIV infection. The unsafe sexual behaviours were associated to the number of sexual partners/year (p=0,007), having steady partner (p= 0,010), having occasional sexual partners (p=0,000) and oral sex practice (receptive oral sex, p=0,001; active oral sex, p= 0,006).The results demonstrated the importance of the secondary prevention on individuals infected by HIV. It also demonstrated the need of providing the attendance centres with a prevention message, teachings and advises to all infected persons as well as to their sexual partners, increasing their life quality and reducing the transmission risk of HIV infection.

Abordagem farmacoepidemiológica da terapêutica no idoso: um ensaio em meio hospitalar

Introdução: O envelhecimento demográfico e o aumento da esperança de vida, criam condições para uma maior incidência de doenças degenerativas. Vários aspectos críticos envolvem a medicação no idoso, tais como: polimedicação frequente, com risco acrescido de ocorrência de reacções adversas, relacionadas com interacções medicamentosas e eventual medicação desaconselhada, em que o risco pode ser superior ao benefício. Estes aspectos são particularmente críticos no idoso hospitalizado. Objectivo: Este estudo teve como objectivo estimar a prevalência da polimedicação em idosos hospitalizados e analisar a medicação considerada inadequada nesta população. Participantes e metodologia: Seguiu-se um modelo retrospectivo descritivo transversal, reportando-se os dados a um período de um ano e meio, incidindo sobre o último internamento. A natureza da medicação, foi analisada de acordo com o Formulário Terapêutico Nacional, Resumo das Caracteristicas do Medicamento e com critérios de Beers-2002.Englobou 100 idosos (>65 anos) utentes do Hospital Cuf Descobertas, em regime de internamento. Os dados pessoais e clínicos e respectivo mapa farmacoterapêutico, foram introduzidos em base de dados construída para este estudo, em Access 2003 SP2. Procedeu-se à analise estatística (SPSS 13,0), descritiva, com cálculo de medidas de tendência central; análise univariada para todas as variáveis relevantes e análise bi-variada para quantificar a prevalência da polimedicação por sexo e grupo etário. Resultados:Dos doentes estudados (65-98 anos), maioritariamente femininos, 7 apresentavam 4 patologias em simultâneo, 13:3 patologias, 27:2 patologias e 30:1 patologia. Em 23 não se verificou qualquer patologia crónica. A hipertensão (n=49:27,5%) e a patologia cardiovascular (n=41:23%) foram as mais frequentemente encontradas na amostra em estudo sendo as de menor frequência a patologia reumática (n=1:0,56%), a osteoporose e os problemas psíquicos (n=2:1,12%. A prevalência de polimedicação foi de 84% e nº de medicamentos prescrito em simultâneo variou entre 2 e 23.Não se observou associação entre a polimedicação, a idade: e o sexo. Em apenas um caso foi identificado um medicamento desaconselhado em função do diagnóstico (metoclopramida:Parkinson), e independentemente do diagnóstico a amiodariona foi o mais frequente (25%), hidroxizina (22%), ticlopidina (2%) e cetorolac (1%). Conclusões: A polimedicação é um fenómeno muito frequente nos idosos hospitalizados; o número de medicamentos envolvidos pode ser elevado e a prevalência de medicamentos que requerem uma ponderação sobre o risco/benefício no idoso, indicia a vantagem da revisão da terapêutica, impondo-se a implementação de estratégias informativas sobre os mesmos. Background: The demographic aging and expansion of life expectancy create conditions for increased occurrence of degenerative illnesses. Several critical aspects involve the medication of the elderly, such as: frequent polipharmacy with increased occurrence of adverse drug reactions, related to medication interactions and inappropriate prescribing, in which the benefits can be inferior to the risks.These aspects are particularly critical in the hospitalized elderly. Aim: This study aimed to estimate the prevalence of polipharmacy in hospitalized elderly and to analyze the medication considered inappropriate in this population. Participants and Methodology: A cross sectional model was followed, in which the data used relate to a period of a year and a half, focussing on the last hospitalization. The nature of the medication was analysed according to National Therapeutic Formulary, Drug Characteristics Summary and according to Beers-2002.It considered 100 elderly (>65 years) hospitalized at Hospital Cuf Descobertas. The personal and clinical data and the corresponding pharmacotherapeutic registration were introduced in a database created for this study in Access 2003 SP2. Descriptive statistics was calculated trough SPSS 13,0,.Exploraty analysis consisted in measures of average and spread for all variable considered relevant and univariate and bivariate analysis to quantify the prevalence of polipharmacy by sex and age and to relate polipharmacy with inappropriate medication. Results: Of the patients studied (65-98 years), the majority were women, 7 presented 4 pathologies, 13:3 pathologies, 27:2 pathologies and 30:1 pathology. In 23 patients there was any chronic pathology. Hypertension (n=49:27,5%) and cardiovascular disease (n=41:23%) were the most frequent disease in our study, and the minimal values were observed in rheumatism (n=1:0,56%), osteoporosis and psychic disorders (n=2:1,12%. The prevalence of polipharmacy was of 84% and the amount of medication simultaneously prescribed varied between 2 and 23.No association was observed between polipharmacy and age or gender. In only one case inappropriate medication was identified concerning diagnosis (metoclopramid: Parkinson), and independent of diagnosis the amiodaron was the most frequent (25%), hydroxyzin (22%), ticlopidin (2%). and ketorolac (1%). Conclusions: Polipharmacy is very prevalent among elderly people admitted to the hospital; the number of inappropriate medication can also be very high and this evidence should be collected in order to accomplish good drug use reviews and informative strategies in the hospital setting.

Braquiterapia prostática: morbilidade urinária e sexual

RESUMO: Objectivos 1. Avaliar a morbilidade urinária e sexual secundária à braquiterapia prostática com implante de I125. 2. Avaliar a influência da hormonoterapia neoadjuvante e adjuvante na morbilidade urinária e sexual secundária à braquiterapia(I125). 3. Avaliar a influência da associação da radioterapia externa na morbilidade urinária e sexual secundária à braquiterapia(I125). 4. Avaliar a morbilidade urinária dos doentes com contra-indicação relativa (próstatas volumosas, IPSS elevado).Material e métodos De Setembro de 2000 a Dezembro de 2004 foram recrutados 204 doentes com o diagnóstico de carcinoma da próstata localizado (T1 e T2) ou localmente avançado (T3) e expectativa de vida superior a 10 anos. Foram submetidos a braquiterapia, com implante transperineal de Iodo 125 (I125) em monoterapia ou combinada com hormonoterapia e/ou radioterapia externa (tratamento trimodal). Definiram-se diversos sub-grupos de pacientes, consoante algumas características habitualmente referidas como factores de risco para a morbilidade do tratamento de braquiterapia prostática, com o objectivo de analisar a sua influência sobre a morbilidade urinária e sexual: Grupo 1: Braquiterapia em monoterapia (MONO) versus braquiterapia associada a radioterapia externa (BCOMB) Grupo 2: Próstatas volumosas (>50ml) versus próstatas não volumosas (<50ml)Grupo 3: Braquiterapia associada a hormonoterapia (HORM) versus braquiterapia sem hormonoterapia (NHORM)Grupo 4: IPSS elevado versus IPSS baixo Avaliou-se a evolução do IPSS, QoL, taxa de RTU-P e retenção urinária pós implante, e evolução do BSFI durante todo o período de seguimento. Resultados Grupo 1: Para o grupo MONO o IPSS iniciou-se com 7.1, sofreu agravamento para 16.1 e 15.9 ao primeiro e terceiro meses. Aos 12 meses, o IPSS desceu para 10.1 enquanto que, aos 18 e 24 meses, o IPSS foi de 7.3 e 5.8. O grupo BCOMB iniciou com IPSS de 9.4. Sofreu agravamento ligeiro e pouco acentuado até aos 6 meses (IPSS de 14). A evolução do IPSS foi, então, flutuante com IPSS de 5.9 aos 12 meses e 9.5 aos 18 meses. Aos 24 meses apresentava IPSS de 6.7. A taxa de retenção urinária (6.4% e 0%) e de RTU-P (2.0% e 0%) foram semelhantes nos grupos MONO e BCOMB, respectivamente (p=0.375 e p=1). A evolução da qualidade das erecções foi semelhante nos dois grupos excepto aos 6 meses em que MONO apresentou o valor 6 e BCOMB 3.7 (p=0.029). A percentagem de doentes potentes foi significativamente inferior nos primeiros 6 meses após a braquiterapia para o grupo BCOMB relativamente ao grupo MONO: 36%–74%; 33%–73%; 33%–75%. Após os 6 meses os grupos foram homogéneos. Grupo 2: O IPSS evoluiu nas próstatas <50ml e >50ml de 7–9 para 15-19 ao primeiro mês e 15-18 ao 3.º mês. Apenas ao primeiro mês é que as diferenças no IPSS foram significativas (p=0.061). Após o 3.º mês os dois grupos foram semelhantes: IPSS de 8 e 12 ao 12.º mês e 5.7 e 6 ao 24.º mês. As taxas de retenção urinária e de RTU-P foram semelhantes (p=0.054 e p=0.286) Grupo 3: A evolução do IPSS, taxas de retenção urinária e de RTU-P foram sobreponíveis em ambos os grupos. A evolução da líbido, erecções, percentagem de doentes potentes, ejaculação, incómodo e satisfação foi significativamente inferior no grupo HORM relativamente ao grupo N HORM apenas ao primeiro mês (valores de p<0.0001; <0.0001; < 0.0001; 0.009 e 0.002 respectivamente) Grupo 4: A evolução do IPSS nos doentes com IPSS elevado foi a seguinte: 22.17(0M); 19.5(1M); 20.5(3M); 15.3(6M); 15.7(12M); 11(18M); 8(24M) A evolução do IPSS nos doentes com IPSS baixo foi a seguinte: 5.9(0M); 15.3(1M); 14.9(3M); 12.2(6M); 8.9(12M); 7.2(18M), 5.5(24M) As taxas de RTU-P (2.8% e 0%) e retenção urinária (5.1% e 5.9%) foram semelhantes em ambos os grupos de doentes (p=1). Conclusões 1. A radioterapia intersticial da próstata com implante transperineal e ecoguiado de Iodo 125 é frequentemente acompanhada de morbilidade urinária transitória e de intensidade moderada. A Morbilidade consiste em sintomatologia do aparelho urinário baixo (“LUTS – lower urinary tract symptoms”) que, na maioria dos doentes, sofre um agravamento máximo do primeiro ao 3.º mês. Segue-se uma melhoria ligeira até ao 6.º mês que é mais acentuada daí em diante. Por volta do 12.º e 18.º mês, a maior parte dos doentes apresenta sintomatologia urinária muito semelhante à que apresentava antes do tratamento. Após o 18.º mês, os doentes mantêm uma melhoria da sintomatologia urinária para além da que apresentavam previamente ao implante. As taxas de retenção urinária e de ressecção transuretral prostática após o implante de braquiterapia são muito baixas, inferiores a 10%. 2. A associação da braquiterapia prostática com radioterapia externa adjuvante influencia a evolução da sintomatologia urinária: o aparecimento da sintomatologia urinária é mais lento, demorando 6 meses a atingir o seu valor máximo que, por sua vez, é de intensidade menos acentuada do que quando a braquiterapia é utilizada em monoterapia. 3. O volume prostático superior a 50 ml não influencia a morbilidade urinária. 4. A terapêutica hormonal, neoadjuvante e adjuvante, não influencia a sintomatologia urinária. 5. Os doentes com sintomatologia urinária prévia muito acentuada não sofrem agravamento da referida sintomatologia. Pelo contrário, apresentam uma melhoria de sintomas urinários desde o primeiro mês, e que se mantém ao longo dos 24 meses de seguimento, apresentando, no final deste período, sintomatologia urinária ligeira e muito inferior à que apresentavam antes do implante. As taxas de retenção urinária e RTU-P após a braquiterapia são semelhantes às que ocorrem nos doentes assintomáticos previamente ao implante. 6. A vida sexual está preservada, em mais de 70% dos casos, ao fim dos 24 meses de seguimento. No entanto, imediatamente após o primeiro mês de seguimento, ocorre uma diminuição ligeira da qualidade das erecções que se mantém, sem melhoria ou agravamento, durante todo o período de seguimento. A hormonoterapia afecta todos os parâmetros da vida sexual, embora de forma apenas temporária. Após a suspensão da terapêutica hormonal este grupo de doentes recupera a actividade sexual e apresenta-se idêntico ao grupo de doentes que não foram sujeitos a essa terapêutica.----------------ABSTRACT: Objectives 1. To assess urinary and sexual morbility after prostatic brachytherapy with the implant of I125 seeds. 2. To assess the influence of neoadjuvant and adjuvant hormone therapy in urinary and sexual morbility after prostatic brachytherapy with the implant of I125 seeds. 3. To assess the effects, on urinary and sexual morbility, of associating external radiotherapy after prostatic brachytherapy with the implant of I125 seeds. 4. To assess the urinary morbility in patients with relative contraindications (voluminous prostates, high IPSS). Material and Methods From September, 2000 to December, 2004 a total of 204 patients were recruited with a diagnosis of localized (T1 and T2) or locally advanced (T3) carcinoma of the prostate and a life expectancy in excess of 10 years. The patients underwent brachytherapy with transperineal seed implant of iodine (I125) as a monotherapy or in combination with hormone therapy and/or external radiotherapy (trimodal treatment). With the aim of evaluating the treatment’s influence on urinary and sexual morbility, a number of patient sub-groups were defined in accordance with certain characteristics normally mentioned as morbility risk factors for prostatic brachytherapy treatment: Group 1: Brachytherapy as monotherapy (MONO) versus brachytherapy in combination with external radiotherapy (BCOMB) Group 2: Voluminous prostates (>50ml) versus non- voluminous prostates (<50ml) Group 3: Brachytherapy in combination with hormone therapy (HORM) versus brachytherapy without hormone therapy (NHORM)Group 4: High IPSS versus a low IPSS. The evolution of the IPSS, QoL, TURP rate and post-implant urinary retention as well as the BSFI were assessed throughout the entire follow-up period. Results Group 1: For the MONO group the IPSS began at 7.1, and then rose to 16.1 and 15.9 in the first and third months, respectively. At month 12, the IPSS had dropped to 10.1 and at month 18 and 24 the IPSS was registered at 7.3 and 5.8, respectively. The BCOMB group started out with an IPSS of 9.4. It underwent a slight and little-significant rise until month 6 (IPSS at 14). The evolution of the IPSS then began to fluctuate from an IPSS of 5.9 at month 12 and 9.5 at month 18. At month 24 we registered an IPSS of 6.7. The urinary retention rate (6.4% and 0%) and TURP rate (2.0% e 0%) were similar to those of the MONO and BCOMB groups, respectively (p=0.375 and p=1). The evolution regarding the quality of erections was similar for the two groups except at 6 months when the MONO group displayed a value of 6 and the BCOMB group 3.7 (p=0.029). The percentage of sexually potent patients was significantly lower in the first six months after brachytherapy for the BCOMB group when compared with the MONO group: 36%–74%; 33%–73%; 33%–75%. After six months, the results became more consistent. Group 2: IPSS results evolved in <50ml and >50ml prostates from 7–9 to 15-19 in the first month and from 15-18 after the third month. It was only in the first month that the differences in the IPSS were significant (p=0.061). After the third month, the two groups displayed similar outcomes: IPSS 8 and 12 at month 12 and 5.7 and 6 at month 24. Urinary retention and TURP rates were similar (p=0.054 e p=0.286). Group 3: IPSS evolution and rates of urinary retention and TURP were identical in both groups. Figures regarding libido, erections, percentage of sexually potent patients, ejaculation, discomfort and sexual satisfaction were always significantly lower for the HORM group, when compared to the NHORM group in the first month only (values of p<0.0001; <0.0001; <0.0001; 0.009 e 0.002, respectively). Group 4: IPSS evolution in patients with a high IPSS was as follows: 22.17(0M); 19.5(1M); 20.5(3M); 15.3(6M); 15.7(12M); 11(18M); 8(24M) IPSS evolution in patients with a low IPSS was as follows: 5.9(0M); 15.3(1M); 14.9(3M); 12.2(6M); 8.9(12M); 7.2(18M), 5.5(24M)TURP rates (2.8% e 0%) and those for urinary retention (5.1% e 5.9%) were similar in both patient groups (p=1). Conclusions 1. Interstitial radiotherapy of the prostate with transperineal, ultrasound-guided implant of Iodine-125 seeds is often followed by transitory urinary morbility of moderate intensity. The morbility involves symptoms of the lower urinary tract which, in most cases are at their worst from the first to the third months. There is a slight improvement up to the sixth month, at which point improvement becomes more accentuated. Around months 12 or 18, most patients display urinary symptoms that are very similar to those noted before treatment. After month 18, patients’ urinary symptoms continue to improve past the point they displayed prior to the implant. Urinary retention rates and those for transurethral resection of the prostate are very low (below 10%), after brachytherapy seed implant. 2. The combination of prostatic brachytherapy and adjuvant external radiotherapy affects the evolution of urinary symptoms: the appearance of urinary symptoms is much slower, taking six months to peak, and is less intense than when brachytherapy is employed as the only means of treatment. 3. The fact that the prostate displays a volume greater than 50 ml does not influence urinary morbility. 4. Neoadjuvant and adjuvant hormone therapy do not influence urinary symptomology. 5. Patients with severe, preexisting symptoms of the urinary tract do not experience a worsening of those symptoms. On the contrary, they exhibit an improvement in urinary symptoms as of the first month. This improvement continues for the 24 months, after which patients display symptoms of the urinary tract that are slight and a noticeable improvement over the urinary complaints registered before the implant. Urinary retention and TURP rates subsequent to brachytherapy are similar to those registered for asymptomatic patients. 6. The patient’s sexual performance is maintained in more than 70% of the cases, as noted after 24 months of follow-up. However, immediately after the first follow-up month there is a lessening in the quality of erections that continues, without improving or worsening, for the whole follow-up period. Hormone therapy affects all the parameters of sexual performance, albeit temporarily. After suspending hormone therapy, this group recovered with regard to sexual performance, and showed itself to be identical to the group of patients that had not undergone hormone therapy.-------------------RESUMÉ:Objectives 1. Évaluer la morbilité urinaire et sexuelle après la realisation la curiethérapie de la prostate avec implant de I125. 2. Évaluer l’ influence de la thérapie hormonale néoadjuvante et adjuvante en ce qui concerne la morbilité urinaire et sexuelle après la réalisation de la curiethérapie (I125). 3. Évaluer l’influence de l’association de la radiothérapie externe dans la morbilité urinaire et sexuelle après la réalisation de la curiethérapie (I125). 4. Évaluer la morbilité urinaire des malades avec des contre indications relatives (prostates volumineuses, IPSS élevé). Matériel et méthodologie De Septembre 2000 à Décembre 2004, on a recruté 204 patients ayant pour diagnostique un carcinome de la prostate localisé (T1 et T2) ou localement avancé (T3) et dont l’expectative de vie était de plus de 10 ans. Ils ont été soumis au traitement de la curiethérapie avec l’implantation transpérinéal de l’iode 125 (I125) en monothérapie ou en traitement combiné avec une thérapie hormonale et/ou radiothérapie externe (traitement trimodale). Il y a eu plusieurs sous-catégories de patients, et cela dépend de quelques caractéristiques normalement considérées comme des facteurs à risque en ce qui concerne la morbilité du traitement de la curiethérapie de la prostate, et l’objective étant d’analyser son influence sur la morbilité urinaire et sexuelle. Groupe 1: Curiethérapie en traitement unique (MONO) par rapport à la curiethérapie associée au traitement externe (BCOMB). Groupe 2: Prostates volumineuses (>50ml) par rapport au prostates qui ne sont pas volumineuses (<50ml). Groupe 3: Curiethérapie associée au traitement hormonale (HORM) par rapport à la curiethérapie sans traitement hormonale (NHORM). Groupe 4: IPSS élevé par rapport au IPSS diminué. Nous avons évalué l’evolution du IPSS, Qualité de vie, le taux de RTU-P et la retention de l’urine après l’implant, BSFI pendant toute la période du traitement. Résultats Groupe 1: Pour le groupe MONO l’IPSS a commençé avec un taux de 7.1, et les patients ont souffert d’un empirement allant jusqu’à 16.1 et 15.9 pendant le premier et le troisième mois. 12 mois après l’IPSS diminua jusqu’à 10.1 À 18 mois le taux fût de 7.3 et à 24 mois il diminua encore jusqu’à atteindre 5.8. Le groupe BCOMB commença avec un taux d’IPSS de 9.4. Ils souffrirent un empirement légér et peu accentué jusqu’aux 6 premiers mois (IPSS de 14). L’évolution de l’IPSS était fluctuante allant de 5.9 à 12 mois et 9.5 à 18 mois. À 24 mois, l’IPSS était de 6.7. Le taux de retention de l’urine (6.4% et 0%) et de la RTU-P (2.0% et 0%) étaient simmilaires dans les groupes MONO et BCOMB respectivement (p=0.375 et p=1). L’ évolution de la qualité des érections fût semblable dans les 2 groupes excepté le groupe MONO qui présenta une valeure de 6 à 6 mois et le groupe BCOMB qui présenta une valeure de 3.7 (p=0.029). Le pourcentage des malades sexuellement puissants a été significativement inférieur pendant les 6 premiers mois depuis la curiethérapie pour le groupe BCOMB si on le compare au groupe MONO: 36%–74%; 33%–73%; 33%–75%. Après cette période, les groupes eûrent des résultats homogénes. Groupe 2: L’ IPSS a évolué dans les prostates <50ml et >50ml de 7–9 jusqu’à 15-19 pendant le premier mois et jusqu’à 15-18 au 3ème mois. C’est seulement pendant le premier mois que les différences de l’IPSS ont été significatives (p=0.061). Après le 3ème mois les deux groupes ont eu des résultats semblables: IPSS 8 et 12 à 12.º mois et 5.7 et 6 à 24.º mois. Le taux de retention de l’urine et de la RTU-P ont été simmilaires (p=0.054 e p=0.286). Groupe 3: L’evolution de l’ IPSS, les taux de retention de l’urine et de la RTU-P pourraient se surposer pour les deux groupes. L’évolution de la libido, des érections, le pourcentage des malades sexuellements puissants, l’incommodité et la satisfaction ont été toujours significativement infériures dans le groupe HORM par rapport au groupe NHORM dès le premier mois (valeurs de p <0.0001; <0.0001; < 0.0001; 0.009 et 0.002 respectivement) Groupe 4: L’évolution de l’ IPSS pour les malades ayant un IPSS élevé fût ainsi: 22.17(0M); 19.5(1M); 20.5(3M); 15.3(6M); 15.7(12M); 11(18M); 8(24M)L’évolution de l’ IPSS pour les malades ayant un IPSS diminué fût ainsi:5.9(0M); 15.3(1M); 14.9(3M); 12.2(6M); 8.9(12M); 7.2(18M), 5.5(24M) Le taux de RTU-P (2.8% e 0%) et de retention de l’urine (5.1% et 5.9%) ont été semblables dans les 2 groupes de malades (p=1). Conclusions 1. La radiothérapie interstitielle de la prostate avec implant transpérinéal de l’iode 125 est fréquamment acompagnée d’une morbilité urinaire transitoire et d’intensité modérée. La morbilité consiste d’une symptomatologie de l’apparéil urinaire inférieure qui, dans la plupart des malades, empire gravement du premier au troisième mois. La situation s’améliore légèrement jusqu’au 6ème mois, l’amélioration étant plus accentuée à partir de là. Autour du 12ème jusqu’au 18ème mois, la majorité des malades présente une symptomatologie urinaire qui se ressemble beaucoup à celle qu’ils avaient avant le traitement. Après le 18ème mois l’amélioration de la symptomatologie urinaire est constante par rapport à celle qu’ils présentaient avant l’implant. Le taux de retention de l’urine et de RTU-P après l’implant de la curiethérapie sont très basses, au dessus de 10%. 2. L’association de la curiethérapie de la prostate avec la radiothérapie externe adjuvante a une influence sur l’évolution de la symptomatologie urinaire: l’apparition des symptômes est plus lente, prenant jusqu’à 6 mois pour atteindre son niveau maximum, qui à son tour, a une intensité moins accentuée que lorsque la curiethérapie est utilisée en monothérapie. 3. Le volume de la prostate supérieure à 50 ml n’a pas d’influence sur la morbilité urinaire. 4. La thérapie hormonale, néoadjuvante et adjuvante, n’a pas d’influence sur la symptomatologie urinaire. 5. Les malades ayant une symptomatologie urinaire préalable et très accentuée ne souffrent pas d’empirement de leur situation. Au contraire, ils présentent une amélioration des symptômes urinaires à partir du premier mois et ceci se maintient tout au long des 24 mois que dure le traitement, ayant à la fin de cette période une symptomatologie urinaire légère et beaucoup plus basse que celle qu’ils présentaient avant l’implant. Le taux de retention de l’urine et de la RTU-P après la curiethérapie est simmilaire à celui que les malades qui n’ont pas de symptômes présentent avant l’implant. 6. La vie sexuelle est préservée dans plus du 70% des cas à la fin de la période de traitement (24 mois). Entretemps, immédiatement après le premier mois d’étude, on note une légère diminution de la qualité des érections qui se maintient sans amélioration ou empirement tout au long du traitement. Le traitement à base d’hormones affecte tous les paramètres de la vie sexuelle, mais de façon temporaire. Après la suspension de la thérapie hormonale ce groupe de malades récupère l’activité sexuelle et se présente de façon égale au groupe de malades qui n’ont pas été soumis à ce traitement.

Determination of human cytomegalovirus genetic diversity in different patient populations in Costa Rica

Seroprevalence of HCMV in Costa Rica is greater than 95% in adults; primary infections occur early in life and is the most frequent congenital infection in newborns. The objectives of this study were to determine the genetic variability and genotypes of HCMV gB gene in Costa Rica. Samples were collected from alcoholics, pregnant women, blood donors, AIDS patients, hematology-oncology (HO) children and HCMV isolates from neonates with cytomegalic inclusion disease. A semi-nested PCR system was used to obtain a product of 293-296 bp of the gB gene to be analyzed by Single Stranded Conformational Polymorphism (SSCP) and sequencing to determine the genetic polymorphic pattern and genotypes, respectively. AIDS patients showed the highest polymorphic diversity with 14 different patterns while fifty-six percent of HO children samples showed the same polymorphic pattern, suggesting in this group a possible nosocomial infection. In neonates three genotypes (gB1, gB2 and gB3), were determined while AIDS patients and blood donors only showed one (gB2). Of all samples analyzed only genotypes gB1, 2 and 3 were determined, genotype gB2 was the most frequent (73%) and mixed infections were not detected. The results of the study indicate that SSCP could be an important tool to detect HCMV intra-hospital infections and suggests a need to include additional study populations to better determine the genotype diversity and prevalence.

Analysis of World Economic Variables Using Multidimensional Scaling

Waves of globalization reflect the historical technical progress and modern economic growth. The dynamics of this process are here approached using the multidimensional scaling (MDS) methodology to analyze the evolution of GDP per capita, international trade openness, life expectancy, and education tertiary enrollment in 14 countries. MDS provides the appropriate theoretical concepts and the exact mathematical tools to describe the joint evolution of these indicators of economic growth, globalization, welfare and human development of the world economy from 1977 up to 2012. The polarization dance of countries enlightens the convergence paths, potential warfare and present-day rivalries in the global geopolitical scene.

A Multidimensional scaling perspective of Rostow's forecasts with the Track-record (1960s-2011) of "pioneers" and "latecomers"

Proceedings of the 12th Conference on Dynamical Systems -Theory and Applications

Massa corporal e aptidão física dos militares da Marinha Portuguesa : distribuição e tendências segundo os indicadores, prevalência e possíveis consequências do excesso de peso

RESUMO - O excesso de peso (EP) é um dos mais graves problemas de Saúde Pública deste século XXI, dada a sua elevada e crescente prevalência a nível mundial, afectando um elevado número de adultos, adolescentes e crianças, com graves consequências na saúde, sendo responsável pelo aumento das doenças crónicas e pela diminuição da duração e qualidade de vida dos indivíduos. Em Portugal, a prevalência do EP afecta mais de metade da população adulta portuguesa. No meio militar, este problema é reflexo da prevalência do EP na população em geral e, para além das consequências económicas e na saúde, prejudica a aparência militar e pode comprometer a aptidão física. Pretende-se com realizar um estudo exploratório, com vista a realizar uma primeira abordagem do conhecimento do perfil e tendências do índice de massa corporal (IMC), bem como da prevalência do EP e, ainda, de possíveis associações entre o EP e a aptidão física, numa amostra representativa de militares no activo da Marinha Portuguesa (MP). Com os resultados deste estudo pretende-se alertar, pela primeira vez, para a problemática do EP no meio militar, contribuindo também para ampliar o conhecimento da prevalência do EP em subgrupos da população nacional. Os resultados obtidos poderão servir de base para a constituição de um sistema de vigilância, para um correcto entendimento da evolução da tendência do IMC e da prevalência de EP dos militares da MP, bem como disponibilizar uma base de partida para outros estudos, focando os determinantes do EP associados a estilos de vida. ------------ABSTRACT - Overweight and obesity severe Public Health problems of the XXI Century due to its high and increasing worldwide prevalence, including Portugal, and it afects a high number of adults, adolescents and children, with serious health consequences, being responsible for the increase of chronic diseases and for lower life quality and lower life expectancy. In Portugal, overweight prevalence affects more than half of adult’s population. Among the Navy, overweight problem reflects population’s tendency, and, besides it’s economic and health consequences, can affect military image and can jeopardize physical fitness with consequences in the Navy response and performance. This study carries out an exploratory first approach of body’s mass index profile and trends, as well the prevalence of overweight in a representative sample of on duty Portuguese Navy staff, and the potential links between overweight and physical fitness among this population. It outcome seeks, for the first time, to draw attention to the overweight problematic among Navy staff, being also a way to enhance the knowledge of overweight prevalence among population sub-groups. It outcome can be a starting point for the set up of monitoring systems, for a correct understanding body’s mass index evolution trends and the prevalence Navy staff overweight, being also a foundation for other studies, foc

Clinical Outcome and Morphologic Analysis after Endovascular Aneurysm Repair Using the Excluder Endograft

OBJECTIVE: Long-term follow-up after endovascular aneurysm repair (EVAR) is very scarce, and doubt remains regarding the durability of these procedures. We designed a retrospective cohort study to assess long-term clinical outcome and morphologic changes in patients with abdominal aortic aneurysms (AAAs) treated by EVAR using the Excluder endoprosthesis (W. L. Gore and Associates, Flagstaff, Ariz). METHODS: From 2000 to 2007, 179 patients underwent EVAR in a tertiary institution. Clinical data were retrieved from a prospective database. All patients treated with the Excluder endoprosthesis were included. Computed tomography angiography (CTA) scans were retrospectively analyzed preoperatively, at 30 days, and at the last follow-up using dedicated tridimensional reconstruction software. For patients with complications, all remaining CTAs were also analyzed. The primary end point was clinical success. Secondary end points were freedom from reintervention, sac growth, types I and III endoleak, migration, conversion to open repair, and AAA-related death or rupture. Neck dilatation, renal function, and overall survival were also analyzed. RESULTS: Included were 144 patients (88.2% men; mean age, 71.6 years). Aneurysms were ruptured in 4.9%. American Society of Anesthesiologists classification was III/IV in 61.8%. No patients were lost during a median follow-up of 5.0 years (interquartile range, 3.1-6.4; maximum, 11.2 years). Two patients died of medical complications ≤ 30 days after EVAR. The estimated primary clinical success rates at 5 and 10 years were 63.5% and 41.1%, and secondary clinical success rates were 78.3% and 58.3%, respectively. Sac growth was observed in 37 of 142 patients (26.1%). Cox regression showed type I endoleak during follow-up (hazard ratio, 3.74; P = .008), original design model (hazard ratio, 3.85; P = .001), and preoperative neck diameter (1.27 per mm increase, P = .006) were determinants of sac growth. Secondary interventions were required in 32 patients (22.5%). The estimated 10-year rate of AAA-related death or rupture was 2.1%. Overall life expectancy after AAA repair was 6.8 years. CONCLUSIONS: EVAR using the Excluder endoprosthesis provides a safe and lasting treatment for AAA, despite the need for maintained surveillance and secondary interventions. At up to 11 years, the risk of AAA-related death or postimplantation rupture is remarkably low. The incidences of postimplantation sac growth and secondary intervention were greatly reduced after the introduction of the low-permeability design in 2004.

Protein adducts from the anti-HIV drug abacavir – possible biomarkers of drug toxicity

Dissertação para obtenção do Grau de Mestre em Genética Molecular e Biomedicina

MORBIDITY AND MORTALITY DUE TO AIDS: A STUDY OF BURDEN OF DISEASE AT A MUNICIPAL LEVEL

Introduction: The purpose of measuring the burden of disease involves aggregating morbidity and mortality components into a single indicator, the disability-adjusted life year (DALY), to measure how much and how people live and suffer the impact of a disease. Objective: To estimate the global burden of disease due to AIDS in a municipality of southern Brazil. Methods: An ecological study was conducted in 2009 to examine the incidence and AIDS-related deaths among the population residing in the city of Tubarao, Santa Catarina State, Brazil. Data from the Mortality Information System in the National Health System was used to calculate the years of life lost (YLL) due to premature mortality. The calculation was based on the difference between a standardized life expectancy and age at death, with a discount rate of 3% per year. Data from the Information System for Notifiable Diseases were used to calculate the years lived with disability (YLD). The DALY was estimated by the sum of YLL and YLD. Indicator rates were estimated per 100,000 inhabitants, distributed by age and gender. Results: A total of 131 records were examined, and a 572.5 DALYs were estimated, which generated a rate of 593.1 DALYs/100,000 inhabitants. The rate among men amounted to 780.7 DALYs/100,000, whereas among women the rate was 417.1 DALYs/100,000. The most affected age groups were 30-44 years for men and 60-69 years for women. Conclusion: The burden of disease due to AIDS in the city of Tubarao was relatively high when considering the global trend. The mortality component accounted for more than 90% of the burden of disease.

Atrial Septal Defects

Atrial septal defects are the third most common type of congenital heart disease. Included in this group of malformations are several types of atrial communications that allow shunting of blood between the systemic and the pulmonary circulations. Most children with isolated atrial septal defects are free of symptoms, but the rates of exercise intolerance, atrial tachyarrhythmias, right ventricular dysfunction, and pulmonary hypertension increase with advancing age and life expectancy is reduced in adults with untreated defects. The risk of development of pulmonary vascular disease, a potentially lethal complication, is higher in female patients and in older adults with untreated defects. Surgical closure is safe and effective and when done before age 25 years is associated with normal life expectancy. Transcatheter closure offers a less invasive alternative for patients with a secundum defect who fulfil anatomical and size criteria. In this Seminar we review the causes, anatomy, pathophysiology, treatment, and outcomes of atrial septal defects in children and adult patients in whom this defect is the primary cardiac anomaly.